Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 4/20 | 0.72 |
| ▸ | CTSS | P25774 | 1/20 | 0.72 |
| ▸ | CTSK | P43235 | 1/20 | 0.72 |
| ▸ | TACR1 | P25103 | 2/20 | 0.70 |
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | ACE | P12821 | 2/20 | 0.65 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.61 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.59 |
| ▸ | KLK7 | P49862 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | CCKBR | P32239 | 3/20 | 0.56 |
| ▸ | CCKAR | P32238 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12267036 | 1.00 | CTSL (0.72) | CTSLCTSSCTSKTACR1MAPT | |
| SCHEMBL7413708 | 0.92 | CTSL (0.71) | CTSLCTSSCTSKTACR1MAPT | |
| SCHEMBL2727405 | 0.92 | CTSL (0.71) | CTSLCTSSCTSKTACR1MAPT | |
| SCHEMBL2727403 | 0.92 | CTSL (0.71) | CTSLCTSSCTSKTACR1MAPT | |
| SCHEMBL850438 | 0.91 | ACE (0.77) | CTSLCTSSCTSKTACR1MAPT | |
| SCHEMBL29367687 | 0.91 | ACE (0.77) | CTSLCTSSCTSKTACR1MAPT | |
| SCHEMBL1003555 | 0.91 | ACE (0.77) | CTSLCTSSCTSKTACR1MAPT | |
| SCHEMBL30976323 | 0.91 | ACE (0.77) | CTSLCTSSCTSKTACR1MAPT | |
| SCHEMBL1486167 | 0.91 | ACE (0.77) | CTSLCTSSCTSKTACR1MAPT | |
| SCHEMBL24378348 | 0.90 | CTSL (0.71) | CTSLCTSSCTSKTACR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221195-A1 | 1,2-DIARYLACETYLENE DERIVATIVES OF ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AG (DE) | 2008-09-11 | — | — | US | disclosed |
| WO-2008071453-A1 | 1,2-DIARYLACETYLENE DERIVATIVES OF ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221195-A1 | 1,2-DIARYLACETYLENE DERIVATIVES OF ACYLTRYPTOPHANOLS | FSHR, GNRHR, TPH1 | CTSL 695/4885CTSS 737/4885CTSK 1174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.